KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Equity Average (2020 - 2026)

AbCellera Biologics filings provide 7 years of Equity Average readings, the most recent being $952.5 million for Q1 2026.

  • Quarterly Equity Average fell 8.37% to $952.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $952.5 million through Mar 2026, down 8.37% year-over-year, with the annual reading at $1.0 billion for FY2025, 8.4% down from the prior year.
  • Equity Average hit $952.5 million in Q1 2026 for AbCellera Biologics, down from $965.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.2 billion in Q4 2022 and bottomed at $952.5 million in Q1 2026.
  • Average Equity Average over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
  • The largest annual shift saw Equity Average rose 28.21% in 2022 before it fell 9.96% in 2025.
  • AbCellera Biologics' Equity Average stood at $1.2 billion in 2022, then dropped by 5.97% to $1.2 billion in 2023, then fell by 8.6% to $1.1 billion in 2024, then dropped by 9.52% to $965.5 million in 2025, then decreased by 1.34% to $952.5 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Equity Average are $952.5 million (Q1 2026), $965.5 million (Q4 2025), and $985.6 million (Q3 2025).